GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Debt-to-Equity

Cangene (FRA:YGE) Debt-to-Equity : 0.00 (As of Oct. 2013)


View and export this data going back to . Start your Free Trial

What is Cangene Debt-to-Equity?

Cangene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2013 was €0.00 Mil. Cangene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2013 was €0.00 Mil. Cangene's Total Stockholders Equity for the quarter that ended in Oct. 2013 was €140.58 Mil. Cangene's debt to equity for the quarter that ended in Oct. 2013 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cangene's Debt-to-Equity or its related term are showing as below:

FRA:YGE's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Cangene Debt-to-Equity Historical Data

The historical data trend for Cangene's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Debt-to-Equity Chart

Cangene Annual Data
Trend Jul04 Jul05 Jul06 Jul07 Jul08 Jul09 Jul10 Jul11 Jul12 Jul13
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cangene Quarterly Data
Jan09 Apr09 Jul09 Oct09 Jan10 Apr10 Jul10 Oct10 Jan11 Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cangene's Debt-to-Equity

For the Biotechnology subindustry, Cangene's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cangene's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cangene's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cangene's Debt-to-Equity falls into.



Cangene Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cangene's Debt to Equity Ratio for the fiscal year that ended in Jul. 2013 is calculated as

Cangene's Debt to Equity Ratio for the quarter that ended in Oct. 2013 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cangene  (FRA:YGE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Cangene Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cangene's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Cangene (FRA:YGE) Business Description

Traded in Other Exchanges
N/A
Address
Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines